TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI; “Accentia”) reports the results of CRSFungal Profile™, a patented, non-invasive diagnostic for Chronic Sinusitis (CS), otherwise known as Chronic Rhinosinusitis (CRS). CRSFungal Profile is the first laboratory diagnostic available for the estimated 31 million Americans that suffer from the debilitating disease. In partnership with the licensee for the technology, IMMCO Diagnostics Inc. (IMMCO) of Buffalo, NY, Accentia has made CRSFungal Profile available to ear, nose and throat (ENT) specialists and allergists nationwide.
